<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0912246378
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEROPENEM KABI.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEROPENEM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        211.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACS Dobfar S.p.A." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACS Dobfar S.p.A.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 606]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALHAYA MEDICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Fresenius Kabi Deutschland GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DH02 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Meropenem Kabi belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections.</p><p style="text-align:justify">Meropenem Kabi is used to treat the following in adults and children aged 3 months and older:</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Infection affecting the lungs (pneumonia)</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Lung and bronchial infections in patients suffering from cystic fibrosis</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Complicated urinary tract infections</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Complicated infections in the abdomen</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Infections that you can catch during or after the delivery</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Complicated skin and soft tissues infections</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Acute bacterial infection of the brain (meningitis)</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Meropenem Kabi may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p style="text-align:justify">&nbsp;</p><p>Meropenem Kabi may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>Do not use Meropenem Kabi</strong></p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic (hypersensitive) to meropenem or any of the other ingredients of this medicine (listed in Section 6).</p><p style="margin-left:18.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if you are allergic (hypersensitive) to other antibiotics such as penicillins, cephalosporins, or carbapenems as you may also be allergic to Meropenem.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt"><strong>Warnings and precautions</strong></p><p style="margin-right:-.1pt; text-align:justify">Talk to your doctor or nurse before using Meropenem:</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-left:1.0cm; text-align:justify; text-indent:-1.0cm">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have health problems, such as liver or kidney problems.</p><p style="margin-left:1.0cm; text-align:justify; text-indent:-1.0cm">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had severe diarrhoea after taking other antibiotics.</p><p style="margin-left:1.0cm; text-align:justify; text-indent:-1.0cm">&nbsp;</p><p style="text-align:justify">You may develop a positive test (Coombs test) which indicates the presence of antibodies that may destroy red blood cells. Your doctor will discuss this with you.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">You may develop signs and symptoms of severe skin reactions (see section 4). If this happens</p><p style="text-align:justify">talk to your doctor or nurse immediately so that they can treat the symptoms</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">If you are not sure if any of the above apply to you, talk to your doctor or nurse before using Meropenem Kabi.</p><p style="margin-right:-.1pt"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt"><strong>Other medicines and Meropenem Kabi</strong></p><p style="margin-right:-.1pt; text-align:justify">Tell your doctor if you are taking, &nbsp;have recently taken or might take any other medicines.</p><p style="margin-right:-.1pt; text-align:justify">This is because Meropenem Kabi can affect the way some medicines work and some medicines can have an effect on Meropenem Kabi.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify">In particular, tell your doctor or nurse if you are taking any of the following medicines:</p><p style="margin-left:17.0pt; margin-right:-.1pt; text-align:justify; text-indent:-17.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Probenecid (used to treat gout).</p><p style="margin-left:1.0cm; margin-right:-.1pt; text-align:justify; text-indent:-1.0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&nbsp;Valproic acid/sodium valproate/valpromide (used to treat epilepsy). Meropenem Kabi should not be used because it may decrease the effect of sodium valproate.</p><p style="margin-left:1.0cm; margin-right:-.1pt; text-align:justify; text-indent:-1.0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Oral anti-coagulant agent (used to treat or prevent blood clots).</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify"><strong>Pregnancyand breast-feeding and fertility</strong></p><p style="text-align:justify">&nbsp;If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is preferable to avoid the use of meropenem during pregnancy.</p><p style="text-align:justify">Your doctor will decide whether you should use Meropenem.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving meropenem. Small amounts of this medicine may pass into the breast milk. Therefore, your doctor will decide whether you should use Meropenem while breast-feeding</p><p style="margin-right:-.1pt; text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt; text-align:justify"><strong>Driving and using machines</strong></p><p style="text-align:justify">No studies on the effect on the ability to drive and use machines have been performed. However, Meropenem Kabi has been associated with headache; tingling or pricking skin(paraesthesiae); and involuntary muscle movements, leading the person&#39;s body to shake rapidly and uncontrollably (convulsions), that are usually accompanied with a loss of consciousness, and any of these could affect your ability to drive or operate machines. Do not drive or use machines if you experience this side effect.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Meropenem Kabi contains sodium.</strong></p><p style="margin-right:-.1pt; text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify">Meropenem 500 mg: This medicine contains 45,13 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 2,3% of the recommended maximum daily dietary intake of sodium for an adult.</p><p style="text-align:justify">Meropenem 1000 mg: This medicine contains 90,25 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 4,5% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p style="text-align:justify">If you have a condition which requires you to monitor your sodium intake please inform your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt">Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p style="margin-right:-.1pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt; text-align:justify"><strong>Use in adults</strong></p><p style="margin-left:7.1pt; margin-right:-.1pt; text-align:justify; text-indent:-7.1pt">- The dose depends on the type of infection that you have, where the infection is in the body and how serious the infection is. Your doctor will decide on the dose that you need.</p><p style="margin-left:7.1pt; margin-right:-.1pt; text-align:justify; text-indent:-7.1pt">- The dose for adults is usually between 500&nbsp;mg (milligrams) and 2&nbsp;g (gram). You will usually receive a dose every 8 hours. However you may receive a dose less often if your kidneys do not work very well.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Use in children and adolescents</strong></p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt">- The dose for children over 3 months old and up to 12 years of age is decided using the age and weight of the child. The usual dose is between 10 mg and 40 mg of Meropenem Kabi for each kilogram (kg) that the child weighs. A dose is usually given every 8 hours. Children who weigh over 50 kg will be given an adult dose.</p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt">&nbsp;</p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt"><strong>How to use Meropenem Kabi</strong></p><p style="text-align:justify">- Meropenem Kabi will be given to you as an injection or infusion into a large vein.</p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt">- Your doctor or nurse will normally give Meropenem Kabi to you.</p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt">- However, some patients, parents and carers are trained to give Meropenem Kabi at home. Instructions for doing this are provided in this leaflet (in the section called &lsquo;Instructions for giving Meropenem Kabi to yourself or someone else at home&rsquo;). Always use Meropenem Kabi exactly as your doctor has told you. You should check with your doctor if you are not sure.</p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt">- Your injection should not be mixed with or added to solutions that contain other medicines.</p><p style="text-align:justify">- The injection may take about 5 minutes or between 15 and 30 minutes. Your doctor will tell you how to give Meropenem Kabi.</p><p style="text-align:justify">- You should normally have your injections at the same times each day.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify"><strong>If you use more Meropenem Kabi than you should</strong></p><p style="text-align:justify">If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p style="margin-right:-.1pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-.1pt; text-align:justify"><strong>If you forget to use Meropenem Kabi</strong></p><p style="margin-right:-.1pt; text-align:justify">If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection.</p><p style="margin-right:-.1pt; text-align:justify">Do not take a double dose (two injections at the same time) to make up for a forgotten dose.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify"><strong>If you stop using Meropenem Kabi</strong></p><p style="margin-right:-.1pt; text-align:justify">Do not stop having Meropenem Kabi until your doctor tells you to.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify">If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-1.45pt; text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Severe allergic reactions</strong></p><p style="text-align:justify">If you have a severe allergic reaction, <strong>stop having </strong><strong>Meropenem Kabi and see a doctor straight away</strong>. You may need urgent medical treatment. The signs may include a sudden onset of:</p><p style="text-align:justify">- Severe rash, itching or hives on the skin.</p><p style="text-align:justify">- Swelling of the face, lips, tongue or other parts of the body.</p><p style="text-align:justify">- Shortness of breath, wheezing or trouble breathing.</p><p>- Serious skin reactions which include</p><p style="margin-left:1.0cm; text-indent:-14.15pt">o Serious hypersensitivity reactions involving fever, skin rash, and changes in the blood tests that check how the liver is working (increased levels of liver enzymes) and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes. These may be signs of a multi-organ sensitivity disorder known as DRESS syndrome.</p><p style="margin-left:1.0cm; text-indent:-14.15pt">o Severe red scaly rash, skin bumps that contain pus, blisters or peeling of skin, which may be associated with a high fever and joint pains.</p><p style="margin-left:1.0cm; text-indent:-14.15pt">o Severe skin rashes that can appear as reddish circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome) or a more severe form (toxic epidermal necrolysis).</p><p style="margin-left:1.0cm; text-indent:-14.15pt"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Damage to red blood cells (not known)</strong></p><p style="text-align:justify">The signs include:</p><p style="text-align:justify">- Being breathless when you do not expect it.</p><p style="text-align:justify">- Red or brown urine.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">If you notice any of the above, <strong>see a doctor straight away</strong>.</p><p style="margin-right:-1.45pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-1.45pt; text-align:justify"><strong>Other possible side effects:</strong></p><p style="text-align:justify"><strong>Common </strong><strong>&nbsp;</strong><strong>(may affect up to 1 in 10 people)</strong></p><p style="text-align:justify">- Abdominal (stomach) pain.</p><p style="text-align:justify">- Feeling sick (nausea).</p><p style="text-align:justify">- Being sick (vomiting).</p><p style="text-align:justify">- Diarrhoea.</p><p style="text-align:justify">- Headache.</p><p style="text-align:justify">- Skin rash, itchy skin.</p><p style="text-align:justify">- Pain and inflammation.</p><p style="text-align:justify">- Increased numbers of platelets in your blood (shown in a blood test).</p><p style="text-align:justify">- Changes in blood tests, including tests that show how well your liver is working.</p><p style="margin-right:-1.45pt"><strong>&nbsp;</strong></p><p style="margin-right:-1.45pt"><strong>Uncommon </strong><strong>&nbsp;</strong><strong>(may affect up to 1 in 100 people)</strong></p><p style="margin-left:7.1pt; text-align:justify; text-indent:-7.1pt">- Changes in your blood. These include reduced numbers of platelets (which may make you bruise more easily), increased numbers of some white blood cells, decreased numbers of other white cells and increased amounts of a substance called &lsquo;bilirubin&rsquo;. Your doctor may do blood tests from time to time.</p><p style="text-align:justify">- Changes in blood tests, including tests that show how well your kidney is working.</p><p style="text-align:justify">- A tingling feeling (pins and needles).</p><p style="text-align:justify">- Infections of the mouth or the vagina that are caused by a fungus (thrush).</p><p style="margin-right:-1.45pt; text-align:justify">- Inflammation of the bowel with diarrhoea.</p><p style="margin-right:-1.45pt; text-align:justify">- Sore veins where Meropenem Kabi is injected.</p><p style="margin-right:-1.45pt; text-align:justify">- Other changes in your blood. The symptoms include frequent infections, high temperature and sore throat. Your doctor may do blood tests from time to time.</p><p style="margin-right:-1.45pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-1.45pt; text-align:justify"><strong>Rare </strong><strong>&nbsp;(may affect up to 1 in 1,000 people)</strong></p><p style="margin-right:-.1pt; text-align:justify">- Fits (convulsions)</p><p style="margin-right:-.1pt; text-align:justify">- Acute disorientation and confusion (delirium)</p><p style="margin-right:-.1pt; text-align:justify"><strong>&nbsp;</strong></p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet.</p><p style="margin-right:-.1pt; text-align:justify">You can also report side effects directly (see details below).By reporting side effects you can help provide more information on the safety of this medicine.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p>To report any side effect(s):</p><p><br /><strong><em>&nbsp;Saudi Arabia:</em></strong></p><p style="margin-left:25.3pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-left:43.3pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p style="margin-left:43.3pt; margin-right:16.95pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:43.3pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Toll free phone: 19999</p><p style="margin-left:43.3pt; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa</p><table cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p style="margin-left:27.0pt; text-indent:-18.0pt"><!--[if !supportLists]--><strong><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><!--[endif]--><strong><em>Other GCC states :</em></strong></p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_5" o:spid="_x0000_s1027"
 type="#_x0000_t202" style='position:absolute;margin-left:-3.7pt;margin-top:6.05pt;
 width:226.75pt;height:21.6pt;z-index:251658240;visibility:visible;
 mso-width-relative:margin;mso-height-relative:margin'/><![endif]--><!--[if !vml]--></p><table cellspacing="0" cellpadding="0"><tbody><tr><td style="background-color:white; border-color:black; vertical-align:top"><!--[endif]--><!--[if !mso]--><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><!--[endif]--><p style="margin-left:36.0pt; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Please contact the relevant competent authority.</p><!--[if !mso]--></td></tr></tbody></table><!--[endif]--><!--[if !mso & !vml]-->&nbsp;<!--[endif]--><!--[if !vml]--></td></tr></tbody></table><p><!--[endif]--><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt; text-align:justify">Keep this medicine out of the sight and reach of children.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="margin-right:-.1pt; text-align:justify">Do not use this medicine after the expiry date which is stated on the container after EXP. The expiry date refers to the last day of that month.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p style="text-align:justify">Do not store above 30&deg;C.</p><p style="text-align:justify">Do not freeze</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Injection </strong></p><p style="text-align:justify">After reconstitution: The reconstituted solutions for intravenous injection should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous injection should not exceed:</p><p style="text-align:justify; text-indent:1.0cm">- 3 hours when stored at up to 25&deg;C;</p><p style="text-align:justify; text-indent:1.0cm">- 12 hours when stored under refrigerated conditions (2-8&deg;C).</p><p style="text-align:justify; text-indent:1.0cm">&nbsp;</p><p style="text-align:justify"><strong>Infusion </strong></p><p style="text-align:justify">After reconstitution: The reconstituted solutions for intravenous infusion should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed:</p><ul><li style="text-align:justify">3 hours when stored at up to 25&deg;C when Meropenem Kabi is dissolved in sodium chloride;</li><li style="text-align:justify">24 hours when stored under refrigerated conditions (2-8&deg;C) when Meropenem Kabi is dissolved in sodium chloride;</li><li style="text-align:justify">1 hour when stored at up to 25&deg;C when Meropenem Kabi is dissolved in dextrose solution;</li><li style="text-align:justify">8 hours when stored under refrigerated conditions (2-8&deg;C) when Meropenem Kabi is dissolved in dextrose solution;</li></ul><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">If not used immediately in-use storage times and conditions are the responsibility of the user.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Do not freeze the reconstituted solution.</p><p style="margin-right:-.1pt; text-align:justify">&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-left:1.0cm; margin-right:-.1pt; text-align:justify; text-indent:-1.0cm"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The active substance is meropenem trihydrate. Each 20&nbsp;ml vial/100&nbsp;ml bottle contains 500&nbsp;mg meropenem. Each 20&nbsp;ml vial ,50&nbsp;ml/100&nbsp;ml bottle contains 1000&nbsp;mg meropenem.</p><p style="margin-left:1.0cm; margin-right:-.1pt; text-align:justify; text-indent:-1.0cm"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->The other ingredient is sodium carbonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Meropenem Kabi is a white or light yellow powder for solution for injection or infusion in vial or bottle.
Meropenem Kabi 500 mg powder for solution for injection or infusion is available in 20 ml glass vials and 100 ml glass bottles.
Meropenem Kabi 1 g powder for solution for injection or infusion is available in 20 ml glass vials, 50 ml and 100 ml glass bottles.
	
Pack sizes of 1 or 10 vials or bottles

Not all pack sizes may be marketed. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="margin-right:-.1pt; text-align:justify"><strong>Marketing Authorisation Holder</strong></p><p style="text-align:justify">Fresenius Kabi Deutschland GmbH</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Manufacturer(s) responsible for batch release</strong></p><p style="margin-right:-.1pt">ACS DOBFAR S.P.A.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي دواء &quot;ميروبينيم كابي&quot; إلى مجموعة من أدوية المُضَادات الحيويَّة تُعرف باسم &quot;الكاربابينيمات&quot;، والتي تعمل على القضاء على البكتريا التي يمكن أن تتسبب في حدوث العدوى الخطيرة.</p><p dir="RTL">وفي هذا السياق، يُستخدَم دواء &quot;ميروبينيم كابي&quot; لعلاج الحالات التالية لدى البالغين والأطفال ممن تبلغ أعمارهم 3 أشهر فما فوق:</p><p dir="RTL" style="margin-left:0cm; margin-right:54.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->العدوى التي تصيب الرئتين (التهاب الرئتين).</p><p dir="RTL" style="margin-left:0cm; margin-right:54.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->التهاب الرئتين والشعب الهوائيَّة لدى المرضى الذين يُعانون من التليُّف الكيسي.</p><p dir="RTL" style="margin-left:0cm; margin-right:54.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->الالتهابات المُزمنة التي تصيب القناة البوليَّة.</p><p dir="RTL" style="margin-left:0cm; margin-right:54.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->الالتهابات الشديدة في البطن.</p><p dir="RTL" style="margin-left:0cm; margin-right:54.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->العدوى التي يمكن أن تحدث لكِ أثناء الولادة أو بعدها.</p><p dir="RTL" style="margin-left:0cm; margin-right:54.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->الالتهابات الشديدة التي يمكن أن تصيب الجلد والأنسجة الرخوة.</p><p dir="RTL" style="margin-left:0cm; margin-right:54.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]-->العدوى البكتيرية الحادة التي تصيب المخ (التهاب السحايا).</p><p dir="RTL">وقد يتم استخدام دواء &quot;ميروبينيم كابي&quot; في علاج المرضى المُصابين بنُدرة المُحببات، والذين يُعانون من الحمى التي يُشتبه أنها ناجمة عن عدوى بكتيرية.</p><p>كما يمكن استخدام دواء &quot;ميروبينيم كابي&quot; لعلاج العدوى البكتيرية بالدم، والتي قد تترافق مع نوع ما من العدوى المذكورة أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تقم باستخدام دواء</strong><strong> </strong><strong>&quot;ميروبينيم</strong><strong> كابي&quot; في أي من الحالات الآتية:</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:43.5pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك حساسية (فرط الحساسية) لعقار الميروبينيم، أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL" style="margin-left:0cm; margin-right:43.5pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت تعاني من الحساسية (فرط الحساسية) للمضادات الحيوية الأخرى (مثل: البنسلين، أو السيفالوسبورين، أو الكاربابينيم)، فقد تكون لديك حساسية من الميروبينيم أيضًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والمحاذير</strong></p><p dir="RTL">لابد من استشارة الطبيب أو الممرضة قبل استخدام الميروبينيم في الحالات الآتية:</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كان لديك مشكلات صحيَّة، مثل: المشكلات التي تصيب الكبد أو الكليتين.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->إذا كنت قد عانيت من إسهال شديد بعد تناوُل مُضادات حيويَّة أخرى.</p><p dir="RTL">وربما تكون نتيجة الاختبار إيجابية لديك (اختبار كومبس)، مما يشير إلى وجود أجسام مُضادة قد تدمر خلايا الدم الحمراء؛ وسوف يناقش طبيبك هذا الأمر معك.</p><p dir="RTL">وقد تظهر لديك علامات ردات الفعل الجلديَّة التحسسية الشديدة وأعراضها (انظر القسم 4)؛ وإذا حدث ذلك، فلابد من استشارة الطبيب أو المُمرضة على الفور من أجل علاج هذه الأعراض.</p><p dir="RTL">وإن لم تكُن متأكدًا ما إذا كان أي مما سبق ينطبق عليك، فلابد من استشارة الطبيب أو المُمرضة قبل استخدام دواء &quot;ميروبينيم كابي&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام دواء &quot;ميروبينيم</strong><strong> كابي&quot; مع الأدوية الأخرى </strong></p><p dir="RTL" style="text-align:justify">لابد من إخبار الطبيب ما إذا كنت تستخدم، أو قد استخدمت حديثًا، أو قد تستخدم قريباً أي أدوية أخرى.</p><p dir="RTL" style="text-align:justify">حيث أنه من الممكن أن يؤدي تعاطي دواء &quot;ميروبينيم كابي&quot; إلى التأثير على طريقة عمل بعض الأدوية الأخرى؛ كما يمكن أن يكون لبعض الأدوية الأخرى تأثير على<strong> </strong>دواء &quot;ميروبينيم كابي&quot;<strong>.</strong></p><p dir="RTL" style="text-align:justify">وبناء على ذلك، لابد من إخبار الطبيب أو المُمرِّضَة ما إذا كنت تتناول أي من الأدوية التالية على وجه الخصوص: &nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->بروبينسيد (يُستخدَم لعلاج النقرس).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حمض الفالبرويك/فالبروات الصوديوم/فالبروميد (يستخدم لعلاج الصرع)، حيث لا يُستخدم دواء &quot;ميروبينيم كابي&quot; في هذه الحالة نظراً لأنه قد يقلل من تأثير &quot;فالبروات الصوديوم&quot;.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الأدوية المُضادة للتجلط التي تُؤخذ عن طريق الفم (التي تُستخدم لعلاج تجلط الدم أو منعه).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL" style="text-align:justify">إذا كنتِ حاملًا، أو ترضعين رضاعة طبيعيَّة، أو تعتقدين بأنكِ من المحتمل أن تكوني حاملًا، أو تخططين لإنجاب طفل قريباً، فلابد من استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء. ويُفضَّل تجنُّب استخدام دواء &quot;ميروبينيم كابي&quot; أثناء فترة الحمل.</p><p dir="RTL" style="text-align:justify">وسوف يُقرر طبيبك ما إذا كان الأمر يستلزم استخدام الميروبينيم.</p><p dir="RTL" style="text-align:justify">ومن الضروري إخبار طبيبك ما إذا كُنتِ ترضعين رضاعة طبيعية أو تنوين البدء في الرضاعة الطبيعيَّة قبل تلقي العلاج باستخدام الميروبينيم، فقد تنتقل كميات صغيرة من هذا الدواء إلى حليب الثدي؛ ومن ثمَّ، سوف يقرر طبيبك ما إذا كان ينبغي عليكِ استخدام الميروبينيم أثناء الرضاعة الطبيعية.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL" style="text-align:justify">لم يتم إجراء أي دراسات حول تأثير هذا الدواء على القدرة على القيادة واستخدام الآلات. وعلى الرغم من ذلك، فقد ارتبط دواء &quot;ميروبينيم كابي&quot; بكل من أعراض: الصداع، أو التنميل، أو وخز الجلد (الإحساس بالخدر)، أو الحركات اللاإرادية بالعضلات، مما يؤدي إلى اهتزاز جسم الشخص سريعًا وبصورة لا يمكن السيطرة عليها (تشنجات)، والتي عادة ما تكون مصحوبة بفقدان الوعي، حيث يمكن أن يؤثر أي من ذلك على قدرتك على القيادة أو تشغيل الآلات. ولذلك، لابد من تجنب القيادة أو استخدام الآلات، في حالة حدوث هذا الأثر الجانبي.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>احتواء دواء &quot;ميروبينيم</strong><strong> كابي&quot; على الصوديوم</strong></p><p dir="RTL" style="text-align:justify"><strong>ميروبينيم</strong><strong> 500 ملجم:</strong> يحتوي هذا الدواء على 45.13 ملجم من الصوديوم (المكون الرئيسي لملح الطعام/ملح &nbsp;الطهي) في كل قنينة. ويُعادِل هذا 2.3% من الحد الأقصى من المدخول الغذائي اليومي من الصوديوم الموصى به لشخص بالغ. &nbsp;&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>ميروبينيم</strong><strong> 1000 ملجم</strong>: يحتوي هذا الدواء على 90.25 ملجم من الصوديوم (المكون الرئيسي لملح الطعام/ملح &nbsp;الطهي) في كل قنينة. ويُعادِل هذا 4.5% من الحد الأقصى من المدخول الغذائي اليومي من الصوديوم الموصى به لشخص بالغ.</p><p dir="RTL" style="text-align:justify">وإذا كان لديك حالة صحيَة تتطلَّب منك ضبط كمية الصوديوم التي تتناولها، فلابد من إبلاغ الطبيب أو المُمرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">تناول هذا الدواء دائمًا وأبدًا وفقاً لما أخبرك به الطبيب أو الصيدلي تماماً؛ وإذا كنت مرتابًا في شيء ما، فلابد من مناقشة الأمر مع طبيبك.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>الاستخدام لدى البالغين</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تعتمد الجرعة على نوع العدوى التي أصابتك، وموضع الإصابة في الجسم، ومدى خطورة العدوى. وسوف يُقرر طبيبك الجرعة التي تحتاجها.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عادة ما تتراوح الجُرعة مع البالغين بين 500 ملجم (ملليجرام) و2 جم (جرام)؛ وعادة ما يتم تعاطي الجرعة كل 8 ساعات. ومع ذلك، فقد تتلقى جرعة أقل في أحيان كثيرة، إذا كانت الكليتان لديك لا تعملان بصورة جيدة.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>الاستخدام مع الأطفال والمراهقين</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تُحدد الجرعة للأطفال ممن تزيد أعمارهم عن 3 أشهر وحتى 12 عامًا وفقاً لعُمر الطفل ووزنه. وتتراوح الجرعة المُعتادة بين 10 ملجم و40 ملجم من دواء &quot;ميروبينيم كابي&quot; لكل كيلوجرام من وزن الطفل. وعادة ما يتم تعاطي الجرعة كل 8 ساعات؛ ويتعاطى الأطفال ممن يزيد وزنهم عن 50 كيلوجرام جرعة البالغين.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>كيفية استخدام دواء</strong><strong> &quot;ميروبينيم كابي&quot;</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->يتم تعاطي دواء &quot;ميروبينيم كابي&quot; في صورة حقن أو تسريب وريدي داخل وريد كبير.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->عادة ما يقوم الطبيب أو المُمرضة بإعطاء دواء &quot;ميروبينيم كابي&quot;.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ومع ذلك، فمن الممكن تدريب بعض المرضى والآباء ومُقدِّمي الرعاية الصحية على إعطاء دواء &quot;ميروبينيم كابي&quot; في المنزل. وتتضمن هذه النشرة التعليمات اللازمة لتنفيذ هذا الأمر (في القسم اللاحق الموضح تحت اسم &quot;تعليمات إعطاء دواء ميروبينيم كابي لنفسك أو لشخص آخر في المنزل&quot;). ولابد من استخدام دواء &quot;ميروبينيم كابي&quot; تمامًا وفقاً لما أخبرك الطبيب، كما ينبغي عليك مناقشة طبيبك في الأمر إذا كنت مرتابًا في شيء ما.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ينبغي عدم خلط حقنتك مع المحاليل التي تحتوي على أدوية أخرى أو تُضاف إليها.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قد يستغرق الحقن حوالي 5 دقائق، أو مابين 15 إلى 30 دقيقة، وسوف يُخبرك الطبيب بشأن كيفية إعطاء دواء &quot;ميروبينيم كابي&quot;.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->لابد من أخذ جميع الحقن في الوقت ذاته يوميًا.</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>في حالة استخدام دواء &quot;ميروبينيم كابي&quot;</strong><strong> بجرعة</strong><strong> أكثر مما ينبغي </strong></p><p dir="RTL" style="text-align:justify">- إذا قمت باستخدام جرعة أكثر من الجرعة الموصوفة لك عن طريق الخطأ، فلابد من الاتصال بالطبيب أو أقرب مستشفى على الفور.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>في حالة إن نسيت استخدام دواء &quot;ميروبينيم كابي&quot; في موعده </strong></p><p dir="RTL" style="text-align:justify">- إذا فاتتك حقنة الدواء، فينبغي أخذها في أقرب وقت ممكن. ومع ذلك، فإذا قد حان وقت الحقنة التالية، فقم بتخطي الحقنة الفائتة.</p><p dir="RTL" style="text-align:justify">- ولا تأخذ جرعة مُضاعفة (حقنتين في الوقت ذاته) من أجل تعويض الجرعة المنسيَّة.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>في حالة التوقف عن استخدام</strong><strong> دواء &quot;ميروبينيم كابي&quot;&nbsp; </strong></p><p dir="RTL" style="text-align:justify">- لا تتوقف عن استخدام دواء &quot;ميروبينيم كابي&quot; حتى يخبرك طبيبك بذلك.</p><p>- وإذا كان لديك أي استفسارات أخرى بشأن استخدام هذا الدواء، فيمكنك استشارة الطبيب أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">يمكن لهذا الدواء أن يتسبب في إحداث بعض الآثار الجانبيَّة مثله مثل جميع الأدوية؛ ومع ذلك، لا تصيب هذه الأعراض جميع المرضى.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>ردود الفعل التحسسية الشديدة</strong></p><p dir="RTL" style="text-align:justify">في حالة الإصابة برد فعل تحسسي شديد، لابد من التوقف عن تناول دواء &quot;ميروبينيم كابي&quot; واستشارة الطبيب على الفور، فقد تحتاج إلى تدخل طبي عاجل. وقد تشتمل العلامات على ظهور مفاجئ لأي مما يلي:</p><p dir="RTL" style="margin-left:0cm; margin-right:39.7pt; text-align:justify; text-indent:-17.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي شديد أو حكَّة أو شرى على الجلد.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.7pt; text-align:justify; text-indent:-17.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->تورُّم الوجه أو الشفتين أو اللسان أو غيرها من أجزاء الجسم.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.7pt; text-align:justify; text-indent:-17.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ضيق في التنفس أو صفير أو مشكلات في التنفس.</p><p dir="RTL" style="margin-left:0cm; margin-right:39.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ردات الفعل الجلدية التحسسية الخطيرة التي تشمل على ما يلي:</p><p dir="RTL" style="margin-left:0cm; margin-right:46.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ردات الفعل الخطيرة لفرط التحسس، والتي تشمل كل من: الحُمى، والطفح الجلدي، والتغيرات التي تطرأ على اختبارات الدم التي تتحقق من الكيفية التي يعمل بها الكبد (زيادة مستويات إنزيمات الكبد)، وزيادة في نوع من أنواع خلايا الدم البيضاء (اليوزينيات)، وتضخُّم الغدد الليمفاويَّة. وقد تكون هذه الأعراض عبارة عن علامات على اضطراب الحساسية متعدد الأعضاء، والذي يُعرف باسم &quot;متلازمة التفاعل الدوائي مع اليوزينيات والأعراض الجهازيَّة DRESS&quot;.</p><p dir="RTL" style="margin-left:0cm; margin-right:46.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي قشري شديد أحمر اللون، وتحدبات جلدية محتوية على صديد، وبثور أو تقشير في الجلد، والتي قد تترافق مع ارتفاع شديد في درجة الحرارة وآلام في المفاصِل.</p><p dir="RTL" style="margin-left:0cm; margin-right:46.75pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي شديد يمكن أن يظهر على شكل بقع دائرية حمراء في كثير من الأحيان، مع بثور تتوسَّط الجذع، وتقشر الجلد، وتقرحات في الفم، والحلق، والأنف، والأعضاء التناسلية، والعينين؛ ويمكن أن يسبقها حمى أو أعراض شبيهة بالأنفلونزا (متلازمة ستيفن جونسون)، أو صورة أكثر حِدة (تَقَشُّر الأَنْسِجَةِ المُتَمَوِّتَةِ البَشْرَوِيَّة).</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>تضرر خلايا الدم الحمراء (غير معروف)</strong></p><p dir="RTL" style="text-align:justify">وتتضمن العلامات كل مما يلي:</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور باحتباس النفس عند عدم تتوقَّع ذلك.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البول أحمر أو بني اللون.</p><p dir="RTL" style="text-align:justify">فإذا لاحظت ظهور أي من الأعراض الواردة أعلاه، <strong>لابد من استشارة الطبيب على الفور</strong>.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>الآثار الجانبية المُحتملة الأخرى</strong></p><p dir="RTL" style="text-align:justify"><strong>آثار جانبيَّة شائعة (</strong><strong>قد تؤثر على ما يصل إلى 1 من كل 10 أفراد)</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم البطن (المعدة).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالمرض (الغثيان).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الشعور بالإعياء (القيء).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الإسهال.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الصُداع.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->طفح جلدي وحكة.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->ألم والتهابات.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->زيادة أعداد الصفائح الدموية في الدم (كما هو موضَّح في اختبار الدم).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حدوث تغيُّرات في اختبار الدم، ويشمل ذلك الاختبارات التي توضِّح مدى كفاءة عمل الكبد لديك.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>آثار جانبيَّة غير شائعة (</strong><strong>قد تؤثر على ما يصل إلى 1 من كل 100 فرد)</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التغيُرات في الدم، ويشمل ذلك انخفاض عدد الصفائح الدمويَّة (مما يجعلك أكثر عُرضة للإصابة بالكدمات بسهولة عن ذي قبل)، وزيادة عدد بعض خلايا الدم البيضاء، وانخفاض عدد خلايا الدم البيضاء الأخرى، وزيادة كميات مادة تسمى &quot;البيليروبين&quot;. وقد يطلب منك الطبيب إجراء اختبارات الدم من آن لآخر.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حدوث تغيُّرات في اختبار الدم، ويشمل ذلك الاختبارات التي توضِّح مدى كفاءة عمل الكليتين لديك.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->شعور بالوخز (دبابيس وإبر).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهابات الفم أو المهبل التي تسببها الفطريات (فطر القُلَاع).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التهاب الأمعاء المصحوب بإسهال.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->قُرحَة الأوردة التي يتم حقن دواء &quot;ميروبينيم كابي&quot; بها.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->التغيُّرات الأخرى التي تحدث في دمك، حيث تتضمن الأعراض كل من: العدوى المُتكررة، وارتفاع درجة الحرارة، والتهاب الحلق. وقد يطلب منك الطبيب إجراء اختبارات الدم من آن لآخر.</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>آثار جانبيَّة نادرة الحدوث (</strong><strong>قد تؤثر على ما يصل إلى 1 من كل 1000 فرد)</strong><strong> </strong></p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->النوبات (التشنُّجَات).</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->حالة حادة من التوهان والارتباك (الهذيان).</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>الإبلاغ عن الآثار الجانبيَّة</strong></p><p dir="RTL" style="text-align:justify">- في حالة الإصابة بأي من الأعراض الجانبيَّة، لابد من استشارة الطبيب أو المُمرِّضَة؛ ويشمل ذلك أي آثار جانبيَّة غير مُدرجَة في هذه النشرة.</p><p dir="RTL" style="text-align:justify">- كما يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل الواردة أدناه).</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>للإبلاغ عن أي أثر (آثار) جانبية</strong>:</p><p dir="RTL" style="margin-left:0cm; margin-right:13.45pt; text-align:justify; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>المملكة العربية السعودية:</strong></p><p dir="RTL" style="text-align:justify"><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-bookmark:_Hlk42986535'></span><span style='mso-element:field-begin;
mso-field-lock:yes'></span><span style='mso-bookmark:_Hlk42986535'><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span><span style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]--><!--[if !mso]--></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><!--[endif]--><p style="text-align:right">المركز الوطني للرعاية الدوائية والسلامة من العقاقير</p><p dir="RTL" style="margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->فاكس: +966-11-205-7662 &nbsp;</p><p dir="RTL" style="margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->للاتصال بالإدارة التنفيذية للتيقظ الدوائي و إدارة الأزمات. هاتف: +966-11-20382222</p><p dir="RTL" style="margin-right:36.0pt; text-align:justify">تحويلة: 2317-2356-2340</p><p dir="RTL" style="margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->مركز الاتصال الموحد: 19999</p><p dir="RTL" style="margin-right:36.0pt; text-align:right; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->البريد الالكتروني: &nbsp;npc.drug@sfda.gov.sa</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->الموقع الالكتروني: www.sfda.gov.sa/npc</p><p dir="RTL" style="margin-left:0cm; margin-right:18.0pt; text-align:justify">&nbsp;</p><!--[if !mso]--></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL" style="margin-left:0cm; margin-right:13.45pt; text-align:right; text-indent:-14.15pt"><!--[if !supportLists]--><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><!--[endif]--><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL" style="text-align:justify"><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-bookmark:_Hlk42986535'></span><span style='mso-element:field-begin;
mso-field-lock:yes'></span><span style='mso-bookmark:_Hlk42986535'><span
dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
dir=LTR></span><span style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></span><![endif]--><!--[if !mso]--></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><!--[endif]--><p dir="RTL" style="text-align:justify">يُرجى التواصُل مع الجهات المُختصة ذات الصلة.</p><!--[if !mso]--></td></tr></tbody></table><p><!--[endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-bookmark:_Hlk42986535'></span><v:shape id="_x0000_i1025" type="#_x0000_t75"
 style='width:226.75pt;height:28.8pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-bookmark:_Hlk42986535'><span style='mso-element:
field-end'></span></span><![endif]--></p><p>&nbsp;</p><p dir="RTL" style="text-align:justify">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">- احتفظ بهذا الدواء بعيدًا عن مرمى بصر ومتناول أيدي الأطفال.</p><p dir="RTL" style="text-align:justify">- لا تقم باستخدام هذا الدواء بعد انتهاء تاريخ صلاحيته المُدوَّن على العبوة والعلبة الكرتون، ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من هذا الشهر المذكور.</p><p dir="RTL" style="text-align:justify">- لا تقم بتخزين الدواء عند درجة حرارة تزيد على درجة 30 درجة مئويَّة.</p><p dir="RTL" style="text-align:justify">- لا تقم بتجميد الدواء.</p><p dir="RTL" style="text-align:justify"><strong>الحقن</strong></p><p dir="RTL" style="text-align:justify"><strong>بعد إعادة التركيب</strong>: ينبغي استخدام المحاليل المُعَاد تركيبها بغرض الحقن الوريدي على الفور، وينبغي ألا يتجاوز الفاصل الزمني بين بداية إعادة تركيب المحلول ونهاية الحقن في الوريد ما يلي:</p><p dir="RTL" style="margin-left:0cm; margin-right:18.15pt; text-align:justify; text-indent:-17.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->3 ساعات عند التخزين حتى 25 درجة مئوية.</p><p dir="RTL" style="margin-left:0cm; margin-right:18.4pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->12 ساعة عند التخزين في ظروف التبريد (2-8 درجة مئوية).</p><p dir="RTL" style="text-align:justify"><strong>&nbsp;</strong></p><p dir="RTL" style="text-align:justify"><strong>التسريب الوريدي</strong></p><p dir="RTL" style="text-align:justify"><strong>بعد إعادة التركيب</strong>: ينبغي استخدام المحاليل المُعَاد تركيبها بغرض التسريب الوريدي على الفور، وينبغي ألا يتجاوز الفاصل الزمني بين بداية إعادة تركيب المحلول ونهاية التسريب في الوريد ما يلي:</p><p dir="RTL" style="margin-left:0cm; margin-right:18.15pt; text-align:justify; text-indent:-17.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->3 ساعات عند التخزين حتى 25 درجة مئوية، عند إذابة دواء &quot;ميروبينيم كابي&quot; في كلوريد الصوديوم.</p><p dir="RTL" style="margin-left:0cm; margin-right:18.15pt; text-align:justify; text-indent:-17.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->24 ساعة عند التخزين في ظروف التبريد (2-8 درجة مئوية)، عند إذابة دواء &quot;ميروبينيم كابي&quot; في كلوريد الصوديوم.</p><p dir="RTL" style="margin-left:0cm; margin-right:18.15pt; text-align:justify; text-indent:-17.85pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->1 ساعة عند التخزين حتى 25 درجة مئوية، عند إذابة دواء &quot;ميروبينيم كابي&quot; في محلول الديكستروز.&nbsp; &nbsp;</p><p dir="RTL" style="margin-left:0cm; margin-right:18.4pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->8 ساعات عند التخزين في ظروف التبريد (2-8 درجة مئوية)، عند إذابة دواء &quot;ميروبينيم كابي&quot; في محلول الديكستروز.</p><p dir="RTL" style="text-align:justify">ومن وجهة النظر الميكروبيولوجية، ما لم تحول طريقة (الفتح / إعادة التركيب / التخفيف) دون حدوث التلوث الميكروبيولوجي، فينبغي استخدام المُنتَج على الفور.</p><p dir="RTL" style="text-align:justify">وإن لم يتم استخدام المُنتَج على الفور، حينئذ، تقع مسئولية ظروف تخزين الدواء قيد الاستعمال وأوقات التخزين على عاتق المستخدِم.</p><p dir="RTL" style="text-align:justify">وينبغي عدم تجميد المحلول المُعَاد تركيبه.</p><p dir="RTL" style="text-align:justify">ولا تقم بالتخلص من أي أدوية عن طريق إلقاءها في مياه الصرف الصحي أو النُفايات المنزليَّة، فلابد من استشارة الصيدلي عن كيفيَّة التخلُّص من الأدوية التي لم تعد تستخدمها؛ فمن شأن تلك التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المادة الفعالة هي &quot;ثلاثي هيدرات الميروبينيم&quot;، حيث تحتوي كل زجاجة (20 مل قنينة / 100 مل) على 500 ملجم من الميروبينيم، وتحتوي كل زجاجة (20 مل قنينة، 50 مل/ 100 مل) على 1000 ملجم من الميروبينيم.</p><p dir="RTL" style="margin-left:0cm; margin-right:36.0pt; text-align:justify; text-indent:-18.0pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->المكوِّن الآخر هو &quot;كربونات الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify">- دواء &quot;ميروبينيم كابي&quot; هو مسحوق أبيض اللون أو أصفر فاتح جاهز للإذابة من أجل الحقن أو التسريب الوريدي في قنينة أو زجاجة.</p><p dir="RTL" style="text-align:justify">- ويتوافر دواء &quot;ميروبينيم كابي&quot; 500 ملجم في صورة مسحوق جاهز للإذابة من أجل الحقن أو التسريب الوريدي في شكل قنينات زجاجيَّة 20 مل أو زجاجات 100 مل.</p><p dir="RTL" style="text-align:justify">- كما يتوافر دواء &quot;ميروبينيم كابي&quot; 1 جم في صورة مسحوق جاهز للإذابة من أجل الحقن أو التسريب الوريدي في شكل قنينات زجاجيَّة 20 مل، وزجاجات 50 مل أو 100 مل.</p><p dir="RTL" style="text-align:justify">- وتحتوي العبوة على 1 أو 10 قنينات أو زجاجات.</p><p dir="RTL" style="text-align:justify">- وقد لا يتم تسويق جميع الأحجام المتاحة للعبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:justify"><strong>الشركة صاحبة رخصة التسويق</strong></p><p dir="RTL">فرينيوس كابي دويتشالند جي إم بي إتش</p><p dir="RTL">&nbsp;</p><p dir="RTL" style="text-align:justify"><strong>الشركة (الشركات) المُصنِّعة المسؤولة عن إصدار التشغيلة الدوائيَّة</strong></p><p dir="RTL">ايه سي أس دوبفار إس بي ايه</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل 2020 م
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Meropenem Kabi 500 mg powder for solution for injection or infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial/bottle contains meropenem trihydrate equivalent to 500 mg anhydrous meropenem.

Excipients:

Meropenem Kabi 500 mg: This medicinal product contains approximately 45,13 mg sodium per vial/bottle, equivalent to 2,3% of the WHO recommended maximum daily intake of 2 g sodium for an adult  

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection or infusion.

A white or light yellow powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Meropenem Kabi is indicated for the treatment of the following infections in adults and children over 3 months of age (see sections 4.4 and 5.1):</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">- Severe pneumonia, including hospital and ventilator-associated pneumonia</p><p style="text-align:justify">- Broncho-pulmonary infections in cystic fibrosis</p><p style="text-align:justify">- Complicated urinary tract infections</p><p style="text-align:justify">- Complicated intra-abdominal infections</p><p style="margin-left:9.0pt; text-align:justify; text-indent:-9.0pt">- Intra- and post-partum infections</p><p style="text-align:justify">- Complicated skin and soft tissue infections</p><p style="text-align:justify">- Acute bacterial meningitis</p><p style="text-align:justify">&nbsp;</p><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>&nbsp;</p><p style="text-align:justify">Meropenem Kabi may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Posology</u></p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The tables 1 and 2 below provide general recommendations for dosing.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. <em>Enterobacteriaceae</em>, <em>Pseudomonas aeruginosa, Acinetobacter </em>spp.), or very severe infections.</p><p style="text-align:justify">Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong><u>Table 1</u></strong></p><p style="text-align:justify"><strong><u>Adults and adolescents</u></strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="height:27.15pt; vertical-align:top; width:284.4pt"><p><strong>Infection </strong></p></td><td style="height:27.15pt; vertical-align:top; width:162.0pt"><p><strong>Dose to be administered </strong></p><p><strong>every 8 hours</strong></p></td></tr><tr><td style="height:25.5pt; vertical-align:top; width:284.4pt"><p>Severe pneumonia including hospital and ventilator-associated pneumonia.</p></td><td style="height:25.5pt; vertical-align:top; width:162.0pt"><p>500 mg or 1 g</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>2 g</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Complicated urinary tract infections</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>500 mg or 1 g</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Complicated intra-abdominal infections</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>500 mg or 1 g</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Intra- and post-partum infections</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>500 mg or 1 g</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Complicated skin and soft tissue infections</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>500 mg or 1 g</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Acute bacterial meningitis</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>2 g</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Management of febrile neutropenic patients</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>1 g</p></td></tr></tbody></table><p>&nbsp;</p><p style="text-align:justify">Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see section 6.2, 6.3 and 6.6).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em><u>Renal impairment</u></em></p><p style="text-align:justify">The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the application of these dose adjustments for a unit dose of 2 g.</p><p>&nbsp;</p><p style="text-align:justify"><strong><u>Table 2</u></strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:120.5pt"><p style="text-align:justify"><strong>Creatinine Clearance</strong></p><p style="text-align:justify"><strong>(ml/min)</strong></p></td><td style="vertical-align:top; width:207.0pt"><p style="text-align:justify"><strong>Dose</strong> (based on &ldquo;unit&rdquo; dose range of 500&nbsp;mg or 1&nbsp;g or 2 g, see table 1 above)</p></td><td style="vertical-align:top; width:117.0pt"><p style="text-align:justify"><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top; width:120.5pt"><p style="text-align:justify">26 -50</p></td><td style="vertical-align:top; width:207.0pt"><p style="text-align:justify">one unit dose</p></td><td style="vertical-align:top; width:117.0pt"><p style="text-align:justify">every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:120.5pt"><p style="text-align:justify">10 -25</p></td><td style="vertical-align:top; width:207.0pt"><p style="text-align:justify">half of one unit dose</p></td><td style="vertical-align:top; width:117.0pt"><p style="text-align:justify">every 12 hours</p></td></tr><tr><td style="vertical-align:top; width:120.5pt"><p style="text-align:justify">&lt;10</p></td><td style="vertical-align:top; width:207.0pt"><p style="text-align:justify">half of one unit dose</p></td><td style="vertical-align:top; width:117.0pt"><p style="text-align:justify">every 24 hours</p></td></tr></tbody></table><p>&nbsp;</p><p style="text-align:justify">Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">There are no established dose recommendations for patients receiving peritoneal dialysis.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em><u>Hepatic impairment</u></em></p><p style="text-align:justify">No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em><u>Elderly </u></em></p><p style="text-align:justify">No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em><u>Paediatric population</u></em></p><p style="text-align:justify"><em><u>&nbsp;</u></em></p><p style="text-align:justify"><em>Children under 3 months of age</em></p><p style="text-align:justify">The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Children from 3 months to 11 years of age and up to 50 kg body weight</em></p><p style="text-align:justify">The recommended dose regimens are shown in the table 3 below:</p><p>&nbsp;</p><p><strong><u>Table 3</u></strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="height:27.15pt; vertical-align:top; width:284.4pt"><p><strong>Infection </strong></p></td><td style="height:27.15pt; vertical-align:top; width:162.0pt"><p><strong>Dose to be administered </strong></p><p><strong>every 8 hours</strong></p></td></tr><tr><td style="height:27.15pt; vertical-align:top; width:284.4pt"><p>Severe pneumonia including hospital and ventilator-associated pneumonia</p></td><td style="height:27.15pt; vertical-align:top; width:162.0pt"><p>10 or 20 mg/kg</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>40 mg/kg</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Complicated urinary tract infections</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>10 or 20 mg/kg</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Complicated intra-abdominal infections</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>10 or 20 mg/kg</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Complicated skin and soft tissue infections</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>10 or 20 mg/kg</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Acute bacterial meningitis</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>40 mg/kg</p></td></tr><tr><td style="height:14.45pt; vertical-align:top; width:284.4pt"><p>Management of febrile neutropenic patients</p></td><td style="height:14.45pt; vertical-align:top; width:162.0pt"><p>20 mg/kg</p></td></tr></tbody></table><p>&nbsp;</p><p style="text-align:justify"><em><u>Children over 50 kg body weight</u></em><em>,</em></p><p style="text-align:justify">The adult dose should be administered.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">There is no experience in children with renal impairment.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Method of Administration</u></p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.</p><p style="text-align:justify">&nbsp;</p><p>For instructions on reconstitution/dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (eg anaphylactic reaction, severe skin reaction) to any other type of betalactam antibacterial agent (e.g. penicillins or cephalosporins).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.</p><p style="text-align:justify">&nbsp;</p><p><em><u>Enterobacteriaceae</u></em><u>, <em>Pseudomonas aeruginosa </em>and <em>Acinetobacter </em>spp. resistance</u></p><p>Resistance to penems of <em>Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter </em>spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Hypersensitivity reactions</u></p><p style="text-align:justify">As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).</p><p style="text-align:justify">Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.</p><p style="text-align:justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p style="text-align:justify">If a severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken. Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see section 4.8). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.</p><p>&nbsp;</p><p style="text-align:justify"><u>Antibiotic-associated colitis</u></p><p style="text-align:justify">Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all antibacterial agents, including meropenem, and may range in severity from mild to life threatening.</p><p style="text-align:justify">Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8). Discontinuation of therapy with meropenem and the administration of specific treatment for <em>Clostridium difficile </em>should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Seizures</u></p><p style="text-align:justify">Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Hepatic function monitoring</u></p><p style="text-align:justify">Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis) (see section 4.8).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).</p><p>&nbsp;</p><p style="text-align:justify"><u>Direct antiglobulin test (Coombs test) seroconversion</u></p><p style="text-align:justify">A positive direct or indirect Coombs test may develop during treatment with meropenem.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Concomitant use with valproic acid/sodium valproate/valpromide</u></p><p style="text-align:justify">The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Meropenem Kabi contains sodium.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Meropenem Kabi 500 mg: This medicinal product contains approximately 2.0 mEq of sodium per 500 mg dose which should be taken into consideration by patients on a controlled sodium diet.</p><p style="text-align:justify">&nbsp;</p><p>Meropenem Kabi 1 g: This medicinal product contains approximately 4.0 mEq of sodium per 1 g dose which should be taken into consideration by patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">No specific medicinal product interaction studies other than probenecid were conducted.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100 % decrease in valproic acid levels in about two days. Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><em>Oral anti-coagulants</em></p><p style="text-align:justify">Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects.</p><p style="text-align:justify">There have been many reports of increases in the anti-coagulant effects of orally administered anticoagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents.</p><p style="text-align:justify">The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.</p><p style="text-align:justify">&nbsp;</p><p><em>Paediatric population</em></p><p style="text-align:justify">Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p style="text-align:justify">There are no or limited amount of data from the use of meropenem in pregnant women.</p><p style="text-align:justify">Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p style="text-align:justify">As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.</p><p style="text-align:justify">&nbsp;</p><p>Breastfeeding</p><p style="text-align:justify">Small amounts of meropenem have been reported to be excreted in human milk. Meropenem Kabi should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesiae and convulsions have been reported for meropenem.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3 %), rash (1.4 %), nausea/vomiting (1.4 %) and injection site inflammation (1.1 %). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6 %) and increased hepatic enzymes (1.5-4.3 %).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p>Tabulated risk of adverse reactions</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In the table 4 below all adverse reactions are listed by system organ class and frequency: very common (&ge; 1/10); common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1,000 to &lt;1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000), not known (cannot be estimated from the available data).</p><p style="text-align:justify">Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>&nbsp;</strong></p><p><strong>Table 4</strong></p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:140.4pt"><p><strong>System OrganClass</strong></p></td><td style="vertical-align:top; width:153.0pt"><p><strong>Frequency</strong></p></td><td style="vertical-align:top; width:170.95pt"><p><strong>Event</strong></p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Infections and infestations</p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>oral and vaginal candidiasis</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Blood and lymphatic system</p></td><td style="vertical-align:top; width:153.0pt"><p>Common</p></td><td style="vertical-align:top; width:170.95pt"><p>thrombocythaemia</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>disorders</p></td><td style="vertical-align:top; width:153.0pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:170.95pt"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>eosinophilia, thrombocytopenia,</p></td></tr><tr><td style="height:41.2pt; vertical-align:top; width:140.4pt"><p><strong>&nbsp;</strong></p></td><td style="height:41.2pt; vertical-align:top; width:153.0pt"><p><strong>&nbsp;</strong></p></td><td style="height:41.2pt; vertical-align:top; width:170.95pt"><p>leucopenia, neutropenia, agranulocytosis, haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Immune system disorders</p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>angioedema, anaphylaxis (see</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:153.0pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:170.95pt"><p>sections 4.3 and 4.4)</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:153.0pt"><p>Common</p></td><td style="vertical-align:top; width:170.95pt"><p>headache</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>paraesthesiae</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:153.0pt"><p>Rare</p></td><td style="vertical-align:top; width:170.95pt"><p>convulsions (see section 4.4)</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:153.0pt"><p>Common</p></td><td style="vertical-align:top; width:170.95pt"><p>diarrhoea, vomiting, nausea,</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:170.95pt"><p>abdominal pain</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>antibiotic-associated colitis (see</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:170.95pt"><p>section 4.4)</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:153.0pt"><p>Common</p></td><td style="vertical-align:top; width:170.95pt"><p>transaminases increased, blood</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:170.95pt"><p>alkaline phosphatase increased</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:170.95pt"><p>blood lactate dehydrogenase increased</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>blood bilirubin increased</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Skin and subcutaneous tissues disorders</p><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>Common</p></td><td style="vertical-align:top; width:170.95pt"><p>rash, pruritis</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p><p>&nbsp;</p><p>&nbsp;</p><p>Not known</p></td><td style="vertical-align:top; width:170.95pt"><p>Urticaria, toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme, (see section 4.4).</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome), acute generalised exanthematous pustulosis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>blood creatinine increased, blood urea increased</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:153.0pt"><p>Common</p></td><td style="vertical-align:top; width:170.95pt"><p>inflammation, pain</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>Uncommon</p></td><td style="vertical-align:top; width:170.95pt"><p>Thrombophlebitis, pain at the injection site</p></td></tr><tr><td style="vertical-align:top; width:140.4pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:153.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:170.95pt"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Paediatric population</p><p>Meropenem Kabi is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p style="margin-left:10.8pt; margin-right:0cm"><strong>To report any side effect(s):</strong></p><p style="margin-left:14.4pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp; <!--[endif]--><strong><em>&nbsp;Saudi Arabia:</em></strong></p><table cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="border-color:black; height:103.2pt; vertical-align:top; width:487.65pt"><p style="margin-left:10.8pt; margin-right:0cm">- The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Fax: +966-11-205-7662</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->SFDA Call center: 19999</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa</p><p style="margin-left:28.8pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&nbsp;</p><p style="margin-left:14.4pt; margin-right:0cm; text-indent:0cm"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><strong><em>Other GCC states :</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In individuals with normal renal function, rapid renal elimination will occur.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Haemodialysis will remove meropenem and its metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: antibacterials for systemic use, carbapenems, ATC code: J01DH02</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Mechanism of action</u></p><p style="text-align:justify">Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Pharmacokinetic/Pharmacodynamic (PK/PD) relationship</u></p><p style="text-align:justify">Similar to other beta-lactam antibacterial agents, the time that meropenem concentrations exceed the MIC (T&gt;MIC) has been shown to best correlate with efficacy. In preclinical models meropenem demonstrated activity when plasma concentrations exceeded the MIC of the infecting organisms for approximately 40 % of the dosing interval. This target has not been established clinically.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Mechanism of resistance</u></p><p style="text-align:justify">Bacterial resistance to meropenem may result from: (1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) (2) reduced affinity of the target PBPs (3) increased expression of efflux pump components, and (4) production of betalactamases that can hydrolyse carbapenems.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Localised clusters of infections due to carbapenem-resistant bacteria have been reported in the European Union.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">There is no target-based cross-resistance between meropenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes. However, bacteria may exhibit resistance to more than one class of antibacterials agents when the mechanism involved include impermeability and/or an efflux pump(s).</p><p>&nbsp;</p><p style="text-align:justify"><strong><u>Breakpoints</u></strong></p><p style="text-align:justify">European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints for MIC testing are presented below.</p><p style="text-align:justify"><strong>Table 5</strong></p><p style="text-align:justify"><strong>EUCAST clinical MIC breakpoints for meropenem</strong> <strong>&nbsp;(2013-02-11, v 3.1)</strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:609px"><tbody><tr><td style="vertical-align:top; width:277.1pt"><p style="text-align:center"><strong>Organism</strong></p></td><td style="vertical-align:top; width:90.0pt"><p>Susceptible (S) (mg/l)</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:90.0pt"><p>Resistant (R) (mg/l)</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Enterobacteriaceae</em><em> </em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Pseudomonas</em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Acinetobacter</em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Streptococcus </em>groups A, B, C, and G</p></td><td style="vertical-align:top; width:90.0pt"><p>note 6</p></td><td style="vertical-align:top; width:90.0pt"><p>note 6</p></td></tr><tr><td style="height:14.55pt; vertical-align:top; width:277.1pt"><p><em>Streptococcus pneumoniae<sup>1</sup></em></p></td><td style="height:14.55pt; vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="height:14.55pt; vertical-align:top; width:90.0pt"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Viridans group streptococci<sup>2</sup></em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:90.0pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:90.0pt"><p><sup>&nbsp;</sup></p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Enterococcus spp.</em></p></td><td style="vertical-align:top; width:90.0pt"><p>--</p></td><td style="vertical-align:top; width:90.0pt"><p>--</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Staphylococcus<sup> </sup>spp<sup>.</sup></em></p></td><td style="vertical-align:top; width:90.0pt"><p>note 3</p></td><td style="vertical-align:top; width:90.0pt"><p>note 3</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Haemophilus influenzae<sup>1,2</sup> </em>and <em>Moraxella catarrhalis<sup>2</sup></em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p><em>Neisseria meningitidis<sup>2,4</sup></em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 0.25</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p>Gram-positive anaerobes except <em>Clostridium difficile</em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 8</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p>Gram-negative anaerobes</p><p><em>Listeria monocytogenes</em></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p><p>&le; 0.25</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 8</p><p>&gt; 0.25</p></td></tr><tr><td style="vertical-align:top; width:277.1pt"><p>Non-species related breakpoints<sup>5</sup></p></td><td style="vertical-align:top; width:90.0pt"><p>&le; 2</p></td><td style="vertical-align:top; width:90.0pt"><p>&gt; 8</p></td></tr></tbody></table><p><sup>1</sup> Meropenem breakpoints for <em>Streptococcus pneumoniae </em>and <em>Haemophilus influenzae </em>in meningitis are &nbsp;0.25 mg/l (Susceptible) and 1 mg/l (Resistant).</p><p style="text-align:justify"><sup>2</sup> Isolates with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC values above the current resistant breakpoint&nbsp; they should be reported as resistant.</p><p style="text-align:justify"><sup>3</sup> Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility</p><p style="text-align:justify"><sup>4</sup> Breakpoints relate to meningitis only.</p><p><sup>5</sup> Non-species related breakpoints have been determined using PK/PD data and are independent of MIC distributions of specific species. They are for use &nbsp;only for organisms that do not have specific breakpoints. Non species related</p><p>breakpoints are based on the following dosages: EUCAST breakpoints apply to meropenem 1000 mg x 3 daily administered intravenously over 30 minutes as the lowest dose. 2 g x 3 daily was taken into consideration for severe infections and in setting the I/R breakpoint.</p><p><sup>6</sup> The beta-lactam susceptibility of streptococcus groups A, B, C and G is inferred from the penicillin susceptibility.</p><p style="text-align:justify"><em>-- </em>= Susceptibility testing not recommended as the species is a poor target for therapy with the drug. Isolates may be reported as R without prior testing.</p><p>&nbsp;</p><p style="text-align:justify">The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The following table of pathogens listed is derived from clinical experience and therapeutic guidelines.</p><p>&nbsp;</p><p><strong>Commonly susceptible species</strong></p><p><u>Gram-positive aerobes</u></p><p><em>Enterococcus faecalis<sup>$</sup></em></p><p><em>Staphylococcus aureus </em>(methicillin-susceptible) <sup>&pound;</sup></p><p><em>Staphylococcus </em>species (methicillin-susceptible) including <em>Staphylococcus epidermidis</em></p><p><em>Streptococcus agalactiae </em>(Group B)</p><p><em>Streptococcus milleri </em>group <em>(S. anginosus, S. constellatus, and S. intermedius)</em></p><p><em>Streptococcus pneumoniae</em></p><p><em>Streptococcus pyogenes </em>(Group A)</p><p>&nbsp;</p><p><u>Gram-negative aerobes</u></p><p><em>Citrobacter freudii</em></p><p><em>Citrobacter koseri</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Haemophilus influenzae</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Morganella morganii</em></p><p><em>Neisseria meningitidis</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus vulgaris</em></p><p><em>Serratia marcescens</em></p><p><em>&nbsp;</em></p><p><u>Gram-positive anaerobes</u></p><p><em>Clostridium perfringens</em></p><p><em>Peptoniphilus asaccharolyticus</em></p><p><em>Peptostreptococcus </em>species <em>(including P. micros, P anaerobius, P. magnus)</em></p><p><em>&nbsp;</em></p><p><u>Gram-negative anaerobes</u></p><p><em>Bacteroides caccae</em></p><p><em>Bacteroides fragilis </em>group</p><p><em>Prevotella bivia</em></p><p><em>Prevotella disiens</em></p><p><em>&nbsp;</em></p><p><strong>Species for which acquired resistance may be a problem</strong></p><p><u>Gram-positive aerobes</u></p><p><em>Enterococcus faecium</em><sup>$&dagger;</sup></p><p>&nbsp;</p><p><u>Gram-negative aerobes</u></p><p><em>Acinetobacter </em>species</p><p><em>Burkholderia cepacia</em></p><p><em>Pseudomonas aeruginosa</em></p><p>&nbsp;</p><p><strong>Inherently resistant organisms</strong></p><p><u>Gram-negative aerobes</u></p><p><em>Stenotrophomonas maltophilia</em></p><p><em>Legionella </em>species</p><p>&nbsp;</p><p><strong>Other micro-organisms</strong></p><p><em>Chlamydophila pneumoniae</em></p><p><em>Chlamydophila psittaci</em></p><p><em>Coxiella burnetii</em></p><p><em>Mycoplasma pneumoniae</em></p><p><em>&nbsp;</em></p><p><sup>$</sup>Species that show natural intermediate susceptibility</p><p><sup>&pound;</sup>All methicillin-resistant staphylococci are resistant to meropenem</p><p><sup>&dagger;</sup>Resistance rate &ge;50% in one or more EU countries.</p><p style="text-align:justify">Glanders and melioidosis: Use of meropenem in humans is based on <em>in vitro B.mallei</em> and <em>B. pseudomallei</em> susceptibility data and on limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of glanders and melioidosis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In healthy subjects the mean plasma half-life is approximately 1 hour; the mean volume of distribution is approximately 0.25 l/kg (11-27 l) and the mean clearance is 287 ml/min at 250 mg falling to 205 ml/min at 2 g. Doses of 500, 1000 and 2000 mg doses infused over 30 minutes give mean Cmax values of approximately 23, 49 and 115 &mu;g/ml respectively, corresponding AUC values were 39.3, 62.3 and 153 &mu;g.h/ml. After infusion over 5 minutes Cmax values are 52 and 112 &mu;g/ml after 500 and 1000 mg doses respectively. When multiple doses are administered 8-hourly to subjects with normal renal function, accumulation of meropenem does not occur.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">A study of 12 patients administered meropenem 1000 mg 8 hourly post-surgically for intra-abdominal infections showed a comparable Cmax and half-life to normal subjects but a greater volume of distribution 27 l.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Distribution</strong></p><p style="text-align:justify">The average plasma protein binding of meropenem was approximately 2 % and was independent of concentration. After rapid administration (5 minutes or less) the pharmacokinetics are biexponential but this is much less evident after 30 minutes infusion. Meropenem has been shown to penetrate well into several body fluids and tissues: including lung, bronchial secretions, bile, cerebrospinal fluid, gynaecological tissues, skin, fascia, muscle, and peritoneal exudates.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Biotransformation</u></p><p style="text-align:justify">Meropenem is metabolised by hydrolysis of the beta-lactam ring generating a microbiologically inactive metabolite. In vitro meropenem shows reduced susceptibility to hydrolysis by human dehydropeptidase-I (DHP-I) compared to imipenem and there is no requirement to co-administer a DHP-I inhibitor.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Elimination</strong></p><p style="text-align:justify">Meropenem is primarily excreted unchanged by the kidneys; approximately 70 % (50 &ndash;75 %) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Faecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Renal insufficiency</strong></p><p style="text-align:justify">Renal impairment results in higher plasma AUC and longer half-life for meropenem. There were AUC increases of 2.4 fold in patients with moderate impairment (CrCL 33-74 ml/min), 5 fold in severe impairment (CrCL 4-23 ml/min) and 10 fold in haemodialysis patients (CrCL &lt;2 ml/min) when compared to healthy subjects (CrCL &gt;80 ml/min). The AUC of the microbiologically inactive ring opened metabolite was also considerably increased in patients with renal impairment. Dose adjustment is recommended for patients with moderate and severe renal impairment (see section 4.2).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Meropenem is cleared by haemodialysis with clearance during haemodialysis being approximately 4 times higher than in anuric patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Hepatic insufficiency</strong></p><p style="text-align:justify">A study in patients with alcoholic cirrhosis shows no effect of liver disease on the pharmacokinetics of meropenem after repeated doses.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Adult patients</strong></p><p style="text-align:justify">Pharmacokinetic studies performed in patients have not shown significant pharmacokinetic differences versus healthy subjects with equivalent renal function. A population model developed from data in 79 patients with intra-abdominal infection or pneumonia, showed a dependence of the central volume on weight and the clearance on creatinine clearance and age.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Paediatric</strong></p><p style="text-align:justify">The pharmacokinetics in infants and children with infection at doses of 10, 20 and 40 mg/kg showed Cmax values approximating to those in adults following 500, 1000 and 2000 mg doses, respectively.</p><p style="text-align:justify">Comparison showed consistent pharmacokinetics between the doses and half-lives similar to those observed in adults in all but the youngest subjects (&lt;6 months t1/2 1.6 hours). The mean meropenem clearance values were 5.8 ml/min/kg (6-12 years), 6.2 ml/min/kg (2-5 years), 5.3 ml/min/kg (6-23 months) and 4.3 ml/min/kg (2-5 months). Approximately 60 % of the dose is excreted in urine over 12 hours as meropenem with a further 12 % as metabolite. Meropenem concentrations in the CSF of children with meningitis are approximately 20 % of concurrent plasma levels although there is significant inter-individual variability.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The pharmacokinetics of meropenem in neonates requiring anti-infective treatment showed greater clearance in neonates with higher chronological or gestational age with an overall average half-life of 2.9 hours. Monte Carlo simulation based on a population PK model showed that a dose regimen of 20 mg/kg 8 hourly achieved 60 %T&gt;MIC for <em>P. aeruginosa </em>in 95 % of pre-term and 91 % of full term neonates.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Elderly</strong></p><p style="text-align:justify">Pharmacokinetic studies in healthy elderly subjects (65-80 years) have shown a reduction in plasma clearance, which correlated with age-associated reduction in creatinine clearance, and a smaller reduction in non-renal clearance. No dose adjustment is required in elderly patients, except in cases of moderate to severe renal impairment (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Animal studies indicate that meropenem is well tolerated by the kidney. Histological evidence of renal tubular damage was seen in mice and dogs only at doses of 2000 mg/kg and above after a single administration and above and in monkeys at 500 mg/kg in a 7-day study.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Meropenem is generally well tolerated by the central nervous system. Effects were seen in acute toxicity studies in rodent at doses exceeding 1000 mg/kg.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The IV LD<sub>50</sub> of meropenem in rodents is greater that 2000 mg/kg.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In repeat dose studies of up to 6 months duration only minor effects were seen including a decrease in red cell parameters in dogs.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">There was no evidence of mutagenic potential in a conventional test battery and no evidence of reproductive toxicity including teratogenic potential in studies in rats up to 750 mg/kg and in monkeys up to 360 mg/kg.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">There was no evidence of increased sensitivity to meropenem in juveniles compared to adult animals.</p><p style="text-align:justify">The intravenous formulation was well tolerated in animal studies.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The sole metabolite of meropenem had a similar profile of toxicity in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium carbonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 ml vials: 4 years
50 and 100 ml bottles: 3 years

After reconstitution:

Intravenous bolus injection administration

A solution for bolus injection is prepared by dissolving the drug product in water for injection to a final concentration of 50 mg/ml. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25°C or 12 hours under refrigerated conditions (2-8°C).
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.
If not used immediately in-use storage times and conditions are the responsibility of the user.

Intravenous infusion administration
A solution for infusion is prepared by dissolving the drug product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20 mg/ml. Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 3 hours at up to 25°C or 24 hours under refrigerated conditions (2-8°C). 
Chemical and physical in-use stability for a prepared solution for infusion using 5% dextrose solution has been demonstrated for 1 hour at 25° or for 8 hours at 2 to 8°C.
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately. 
If not used immediately in-use storage times and conditions are the responsibility of the user.

The constituted solutions should not be frozen.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Do not store above 30 &deg;C.</p><p style="text-align:justify">Do not freeze.</p><p style="text-align:justify">&nbsp;</p><p>For storage conditions after reconstitution/dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0cm; margin-right:0cm; text-align:justify">20&nbsp;ml glass vials and 100 ml colourless glass bottles, closed with bromobutilic rubber stopper and sealed with aluminium caps</p><p>&nbsp;</p><p>The medicinal product is supplied in pack sizes of 1 or 10 vials/bottles.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify">Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Injection</u></p><p style="text-align:justify">Meropenem to be used for bolus intravenous injection should be constituted with sterile water for</p><p style="text-align:justify">injection.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Infusion</u></p><p style="text-align:justify">For intravenous infusion meropenem vials/bottles may be directly constituted with 0.9 % sodium chloride or 5% glucose solutions for infusion.</p><p style="text-align:justify">Each vial/bottles is for single use only.</p><p style="text-align:justify">Standard aseptic techniques should be used for solution preparation and administration.</p><p style="text-align:justify">The solution should be shaken before use.</p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify">Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Fresenius Kabi Deutschland GmbH
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 April 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>